---
title: "IM Cannabis Corp. (IMCC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IMCC.US.md"
symbol: "IMCC.US"
name: "IM Cannabis Corp."
industry: "Pharmaceuticals"
datetime: "2026-05-21T13:31:23.081Z"
locales:
  - [en](https://longbridge.com/en/quote/IMCC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IMCC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IMCC.US.md)
---

# IM Cannabis Corp. (IMCC.US)

## Company Overview

IM Cannabis Corp. engages in importation, distribution and sale of medical cannabis products in Israel and Germany. It provides medical cannabis dried flowers; and full-spectrum cannabis extracts under the IMC, BLKMT, and LOT420 brands. The company serves medical patients.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [imcannabis.com](https://imcannabis.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: D (0.70)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 167 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.38% |  |
| Net Profit YoY | -199.60% |  |
| P/B Ratio | -0.42 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1511022.82 |  |
| Revenue | 36918946.19 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -10161.90% | E |
| Profit Margin | -27.25% | E |
| Gross Margin | 16.35% | D |
| Revenue YoY | -5.38% | D |
| Net Profit YoY | -199.60% | E |
| Total Assets YoY | -45.79% | E |
| Net Assets YoY | -265.97% | E |
| Cash Flow Margin | -0.48% | D |
| OCF YoY | -5.38% | D |
| Turnover | 1.48 | A |
| Gearing Ratio | 121.62% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - IM Cannabis Corp.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.38%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-199.60%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.42",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1511022.82",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "36918946.19",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-10161.90%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-27.25%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "16.35%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-5.38%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-199.60%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-45.79%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-265.97%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-0.48%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-5.38%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "1.48",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "121.62%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.15 | 72/190 | - | - | - |
| PB | -0.42 | 207/190 | 4.00 | 2.67 | 2.19 |
| PS (TTM) | 0.04 | 3/190 | 0.27 | 0.21 | 0.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2024-11-14T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.24 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IMCC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IMCC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IMCC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IMCC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**